Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001886431Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	ALNYLAM PHARMACEUTICALS, INC.			
SEC File Number	001-36407			
Address of Issuer	675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MASSACHUSETTS 02142			
Phone	(617) 551-8200			
Name of Person for Whose Account the Securities are To Be Sold	Fitzgerald Kevin Joseph			
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose				

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	22025	5936178.00	128380513	08/12/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you

Nature of

Is Date

Amount of

Date of

Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Donor Acquired	Securities Acquired	Payment	Payment *
Common	08/12/2024 Ex	xercise of stock	Issuer		20725	08/12/2024 Ca	ash
Common	06/24/2024 PS	SU	Issuer		1300	06/24/2024 N	A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report **I**

144: Remarks and Signature

ATTENTION:	
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/10/2024
e of Notice	08/12/2024
Remarks	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kevin Fitzgerald

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)